Abstract presentations and workshops at ERS 2015 highlight ResMed’s dedication to evidence-based medicine and to building the knowledge-base on sleep-disordered breathing and respiratory conditions
Amsterdam, 26 September 2015 – ResMed (NYSE: RMD) today announced new data will be presented at the 2015 European Respiratory Society International Congress (ERS) that addresses:
- Gender-specific treatment needs in obstructive sleep apnea (OSA) and the efficacy of ResMed’s AirSense 10 AutoSet for Her device in treating females with OSA
- New information from the ORCADES multi-center cohort study that highlights the benefits of the Narval CC™ device in managing mild-to-severe OSA in patients who refuse or do not tolerate continuous positive airway pressure (CPAP) therapy. ORCADES is the largest prospective multi-center observational cohort study ever undertaken on custom mandibular repositioning devices (MRD), providing long-term data (five years follow-up) on 360 OSA patients. The study demonstrates the ResMed Narval CC™ MRD is effective and well tolerated, and may also have beneficial effects on cardiovascular parameters including arterial hypertension
- The benefits of non-invasive positive pressure ventilation (NIV) in treating patients with severe stable chronic obstructive pulmonary disease (COPD)
- The link between sleep-disordered breathing and serious diseases like chronic heart failure and chronic obstructive pulmonary disease (COPD)
- Updated findings from the SERVE-HF study and FACE registry on the management of central sleep apnea (CSA) with Adaptive Servo-Ventilation (ASV), and their implication for clinical practice.
“ResMed’s aim is to optimize the connection between patients and healthcare providers to maximize the quality of care that patients with sleep-disordered breathing and other respiratory insufficiencies receive,” said Anne Reiser, president of ResMed Europe and Asia Pacific. “With several types of treatment available for sleep disordered breathing, we are committed to ensuring patients have options available to fit their specific needs and lifestyle. The new information we are presenting at ERS 2015 addresses both the unique requirements and differences between OSA treatment available for men and women as well as the personalized solutions for patients who do not comply with prescribed CPAP therapy.”
“Sleep-disordered breathing is associated with a number of serious cardiovascular and respiratory diseases, including hypertension, stroke and COPD. ResMed is dedicated to rigorous, evidence-based medicine to learn where addressing sleep-disordered breathing could improve outcomes for patients.”
ResMed is supporting four presentations at ERS 2015:
- Late-breaking abstract: “SERVE-HF: assessment of effects of Adaptive Servo-Ventilation on morbidity and mortality in patients with symptomatic Chronic Heart Failure with reduced Left Ventricular Ejection Fraction and predominant Central Sleep Apnea” M. Cowie (London, United Kingdom) on Tuesday 29th September from 10:45 to 12:45 in Room Elicium 1
- Poster: “Current Automatic CPAP Devices exhibit different responses when tested with an improved simulator of OSA patient” on Tuesday 29th September from 08:30-10:30, Room 13.2 (Abstract number: n°254)
- Poster: “Impact of a custom-made Mandibular Repositioning Device on blood pressure in Obstructive Sleep Apnea patients noncompliant with Continuous Positive Airway Pressure” on Monday 28th September from 12:50-14:40, Hall 14-16 (Abstract number: n°3459)
- Oral presentation: “ASV decreases unplanned hospitalisations in chronic heart failure (CHF) patients with CSA: The French multicentre, prospective FACE cohort study JL. Pépin (Grenoble, France)” on Wednesday 30th September from 08:30-10:30, Room 5.1 (Abstract number: n°1459)
ResMed will be holding the following practical workshops and mini-symposiums during the congress:
- Workshop: “Practical focus on recent innovations to optimise sleep apnea patients’ compliance and quality of care” on Sunday 27th September from 13:15-14:30, Room E102 (E Area)
- Workshop: "Perspectives for ASV therapy in Complex Sleep Disordered Breathing – interactive clinical cases" on Tuesday 29th September from 13:15-14:30, Room E102 (E Area)
- Workshop: “Best practice in Life-Support and Non-Life-Support – meet the experts” on Monday 28th September from 13:15-14:30, Room E108
- Mini-symposium: “Long-term non-invasive ventilation (NIV) in COPD – who and when?” on Sunday 27th September from 17:30-19:00, Room D201-202 (Elicium)
- Mini-symposium: “Sleep-Disordered Breathing in HF, SERVE-HF results and beyond” on Monday 28th September from 17:30-19:00, Room Emerald (Auditorium)
Visit ResMed’s booth at 1.J_04 at the ERS Congress from 26th-30th September 2015.
Additional information about ResMed's activities can be obtained via: http://www.ResMedatERS.com
# ENDS #
NOTES TO EDITORS
About Sleep-Disordered Breathing (SDB)
SDB is a term commonly used to describe abnormal breathing during sleep. It usually refers to a patient whose breathing rate increases and/or decreases in an unusual fashion, leading to pauses in breathing and reduced blood oxygen saturation levels.1 SDB has been linked to a number of potentially harmful health issues including cardiovascular complications such as heart failure.1
About Chronic Obstructive Pulmonary Disease (COPD)
COPD is a term used to describe a collection of lung diseases including chronic bronchitis, emphysema and chronic obstructive airways disease.2 COPD patients experience difficulties in breathing, primarily due to the narrowing of their airways (airflow obstruction).2 An acute exacerbation of COPD is a flare up of the condition, when a COPD patient’s breathing gets worse than usual due to infection.3
About ResMed Therapies
- AirSense™ 10 AutoSet™ for Her - Women with SDB present with different symptoms than men. The AirSense 10 AutoSet for Her device delivers a unique, clinically proven, two auto-adjusting algorithm designed to treat mild-to-moderate SDB in women. To complement this device, ResMed also offers a range of ultra-light and compact masks tailored to fit females.
- Narval CC™ - The custom-made mandibular repositioning device (MRD), Narval CC™, incorporates patented physiological articulation and unique comfortable splints to optimise patient acceptance and treatment efficacy. It was designed to avoid dental and temporo-mandibular joint side-effects that are common in traditional respiratory devices. ResMed remains unique in having a dental MRD as part of its main sleep product portfolio to ensure patients and practitioners have all the tools they need to enable improved efficacy and outcomes.
- AcuCare™ - AcuCare™ features a range of innovative, high quality disposable patient interfaces for the hospital, including a high-performing nasal cannula (HFNC) for high flow oxygen therapy (HFOT) and a family of easy-to-use masks for NIV.
- Lumis - Lumis is the first ResMed ventilation solution with IntelligentAir, a collection of ResMed technologies that can tailor therapy to individual breathing needs. The complete IntelligentAir suite for Lumis includes: iVAPS (ResMed’s unique volume-assurance therapy mode), iBR (intelligent Backup Rate), and AutoEPAP (to maintain upper airway patency), as well as other features to personalise patient’s synchrony and comfort (Vsync, TiControlTM, built-in HumidAir™ and trigger and cycle settings).
- myAir™ - ResMed’s personalised therapy management application for patients with SDB, myAir™ provides patients with well-timed support, education and troubleshooting tools to provide them with the confidence and motivation to start and stay on therapy. myAir™ helps drive operational efficiencies for home care providers and hospitals, whilst also empowering patients to take an active role in their health.
- AirView Diagnostic - As an integrated tool within ResMed’s AirView secure patient management solution, AirView Diagnostic allows home sleep tests to be shared between the referrer and sleep lab, achieved by saving results to a centrally stored and secure database, giving physicians access from anywhere where they have an internet connection. Supporting ApneaLink Air home sleep testing device and now Nox T3 PG device too, it offers comprehensive analysis in the cloud, with manual scoring capability and innovative eSignature reporting within the browser removing the need to continually update software.
The global team at ResMed (NYSE:RMD) is united in the commitment to change millions of lives with every breath. With more than 4,000 employees and a presence in over 100 countries, the company has been pioneering new and innovative devices and treatments for sleep-disordered breathing, chronic obstructive pulmonary disease, and other chronic diseases for more than 25 years. ResMed's world-leading products and innovative solutions improve the quality of life for millions of patients worldwide, reduce the impact of chronic disease, and save healthcare costs. For more information about ResMed and its businesses, visit www.resmed.com or follow @resmed on Twitter.
For News Media
Marketing Communications Director
+33 6 21 83 72 33
Senior Director, Investor Relations
+1 (858) 836-5971